DIDRONEL Drug Patent Profile

When do Didronel patents expire, and when can generic versions of Didronel launch?

Didronel is a drug marketed by Mgi Pharma Inc and Apil and is included in two NDAs.

The generic ingredient in DIDRONEL is etidronate disodium. There are four drug master file entries for this compound. Additional details are available on the etidronate disodium profile page.

Summary for DIDRONEL

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	63
Clinical Trials:	2
DailyMed Link:	DIDRONEL at DailyMed

Recent Clinical Trials for DIDRONEL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Assistance Publique - Hôpitaux de Paris	Phase 3
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Phase 3
Eisai Co., Ltd.	Phase 3

See all DIDRONEL clinical trials

US Patents and Regulatory Information for DIDRONEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mgi Pharma Inc	DIDRONEL	etidronate disodium	INJECTABLE;INJECTION	019545-001	Apr 20, 1987		DISCN	No	No
Apil	DIDRONEL	etidronate disodium	TABLET;ORAL	017831-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Apil	DIDRONEL	etidronate disodium	TABLET;ORAL	017831-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Expired US Patents for DIDRONEL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apil	DIDRONEL	etidronate disodium	TABLET;ORAL	017831-001	Approved Prior to Jan 1, 1982
Mgi Pharma Inc	DIDRONEL	etidronate disodium	INJECTABLE;INJECTION	019545-001	Apr 20, 1987
Mgi Pharma Inc	DIDRONEL	etidronate disodium	INJECTABLE;INJECTION	019545-001	Apr 20, 1987

International Patents for DIDRONEL

See the table below for patents covering DIDRONEL around the world.

Country	Patent Number	Title	Estimated Expiration
Finland	44411
United Kingdom	1145909
African Intellectual Property Organization (OAPI)	2258

Market Dynamics and Financial Trajectory for Didronel (Etidronate)

Last updated: March 19, 2026

What is Didronel (Etidronate), and what are its current indications?

Didronel (etidronate) is a bisphosphonate medication approved primarily for treating Paget’s disease of bone. It also manages heterotopic ossification and, historically, was used in osteoporosis treatment. As of 2023, its patent exclusivity has expired, leading to generic versions entering the market.

How has the market for Didronel evolved over recent years?

Market size and growth

• The global bisphosphonate market was valued at approximately $6.2 billion in 2022.
• Paget’s disease treatments represented a small, declining segment due to reduced awareness and diagnosis.
• The osteoporosis segment remains dominant, but Didronel's share has diminished in favor of newer agents like zoledronic acid and denosumab.

Drivers

• Aging populations increase the prevalence of osteoporosis, indirectly supporting bisphosphonate demand.
• Limited newer alternatives for Paget's disease restrict substitution options for Didronel.
• Generic availability reduces prices and expands access, especially in developing markets.

Constraints

• Safety concerns, including osteonecrosis of the jaw and atypical femoral fractures, limit off-label use.
• Lack of new formulations or indications diminishes growth prospects.
• Competition from newer bisphosphonates with less side effects.

Geographic trends

• North America and Europe hold the majority of the bisphosphonate market due to higher diagnosis rates.
• Emerging markets show increasing demand driven by aging demographics and expanding healthcare infrastructure.

What is the current patent and regulatory status?

• Didronel's patent protection expired in 2007.
• Multiple generics have FDA approval since 2008, leading to significant price erosion.
• No recent regulatory updates or new approvals for new indications.

How does commercial competition impact Didronel’s financial outlook?

Competitor	Status	Market Share	Key Features
Fosamax (alendronate)	Patented until 2005; generic available since	Dominant in osteoporosis	No longer first-line in Paget’s
Boniva (ibandronate)	Patented until 2012; generic now	Moderate	Focused on osteoporosis
Zoledronic acid (Reclast, Zometa)	Patent expired; proprietary formulations	Increasing	High efficacy, IV administration
Denosumab (Prolia, Xgeva)	Patent expiring in 2025	Growing	Monoclonal antibody, different mechanism

Didronel's market share declined sharply after patent expiry. The competitive landscape favors drugs with better safety profiles, dosing convenience, and targeted indications. Pricing pressure from generics further constrains revenues.

What are the financial prospects for Didronel moving forward?

Revenue projections

• Current revenues are minimal, primarily from existing supply agreements and off-label usage.
• No new clinical developments or approved indications limit growth potential.
• Future revenues depend on generic market share retention, which is limited by competition.

Cost considerations

• Manufacturing costs decrease with generic production.
• Limited investment needed for R&D, given the aging patent status.
• Market share erosion likely continues without reinvestment in new indications.

Strategic outlook

• No strategic initiatives announced for reformulation or new indications.
• Market exposure remains tied to the broader bisphosphonate landscape, which is mature and highly competitive.

What are the key regulatory and policy influences?

• Increased regulatory scrutiny on safety issues may influence usage patterns.
• Healthcare policies favor cost-effective generics, supporting price competition.
• No recent regulatory barriers hinder generic sales or manufacturing.

Summary

Didronel (etidronate) has a stable but declining niche in Paget’s disease management. Market growth is limited due to safety concerns, the availability of newer therapies, and a mature generic landscape. Its financial trajectory is flat, with minimal revenue potential absent new indications or formulations. Continued competition and pricing pressures define its future market presence.

---

Key Takeaways

• Didronel markets primarily in Paget’s disease; side effects and competition limit growth.
• Patent expiry in 2007 led to broad generic adoption, compressing margins.
• Dominant competitors include zoledronic acid and denosumab, which capture larger market shares.
• Future revenue streams are minimal; focus remains on cost-effective generic manufacturing.
• Regulatory and policy trends favor newer drugs with better safety profiles, further challenging Didronel’s relevance.

---

FAQs

1. Will Didronel regain market share in the future?

Unlikely. Market dynamics favor advanced bisphosphonates with better safety profiles and convenience. No plans for reformulation or new indications support a resurgence.

2. How significant is the generic competition for Didronel?

It is the primary market influence. Multiple generics are available globally, leading to price reductions and limited margins.

3. Are there any upcoming regulatory changes that might affect Didronel?

No current regulatory changes specifically target Didronel, though evolving safety regulations impact bisphosphonate prescriptions overall.

4. Could new indications revitalize Didronel’s sales?

Possible but unlikely. No clinical trials or regulatory filings suggest plans for new uses, and the drug’s safety profile limits potential.

5. How does Didronel compare with newer bisphosphonates financially?

Newer agents like zoledronic acid and denosumab command higher prices, better patient adherence, and broader indications, making Didronel less financially competitive.

---

References

[1] MarketWatch. (2023). Global bisphosphonate market report.
[2] U.S. Food and Drug Administration. (2022). Drug approvals and label updates.
[3] Grand View Research. (2022). Osteoporosis drugs market analysis.